Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1981 2
1982 1
1983 3
1985 3
1986 1
1987 2
1988 2
1989 1
1990 2
1991 3
1992 5
1993 1
1994 2
1995 2
1996 6
1997 3
1998 6
1999 5
2000 7
2001 7
2002 6
2003 7
2004 7
2005 6
2006 4
2007 8
2008 10
2009 9
2010 5
2011 5
2012 8
2013 13
2014 21
2015 25
2016 19
2017 14
2018 20
2019 21
2020 14
2021 9
2022 13
2023 9
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

297 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Melanoma Metastatic in the Central Nervous System"
Page 1
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.
Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, Atkins MB, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Thomas RP, Tarhini A, Pavlick AC, Jiang J, Avila A, Demelo S, Margolin K. Tawbi HA, et al. N Engl J Med. 2018 Aug 23;379(8):722-730. doi: 10.1056/NEJMoa1805453. N Engl J Med. 2018. PMID: 30134131 Free PMC article. Clinical Trial.
BACKGROUND: Brain metastases are a common cause of disabling neurologic complications and death in patients with metastatic melanoma. Previous studies of nivolumab combined with ipilimumab in metastatic melanoma have excluded patients with untreated br …
BACKGROUND: Brain metastases are a common cause of disabling neurologic complications and death in patients with metastatic melano …
Management of immune-related adverse events and kinetics of response with ipilimumab.
Weber JS, Kähler KC, Hauschild A. Weber JS, et al. J Clin Oncol. 2012 Jul 20;30(21):2691-7. doi: 10.1200/JCO.2012.41.6750. Epub 2012 May 21. J Clin Oncol. 2012. PMID: 22614989 Review.
Monoclonal antibodies directed against the immune checkpoint protein cytotoxic T-lymphocyte antigen-4 (CTLA-4; CD152)-ipilimumab and tremelimumab-have been investigated in metastatic melanoma and other cancers and have shown promising results. Recently, ipilimumab w …
Monoclonal antibodies directed against the immune checkpoint protein cytotoxic T-lymphocyte antigen-4 (CTLA-4; CD152)-ipilimumab and tremeli …
Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition.
Ngo B, Kim E, Osorio-Vasquez V, Doll S, Bustraan S, Liang RJ, Luengo A, Davidson SM, Ali A, Ferraro GB, Fischer GM, Eskandari R, Kang DS, Ni J, Plasger A, Rajasekhar VK, Kastenhuber ER, Bacha S, Sriram RK, Stein BD, Bakhoum SF, Snuderl M, Cotzia P, Healey JH, Mainolfi N, Suri V, Friedman A, Manfredi M, Sabatini DM, Jones DR, Yu M, Zhao JJ, Jain RK, Keshari KR, Davies MA, Vander Heiden MG, Hernando E, Mann M, Cantley LC, Pacold ME. Ngo B, et al. Cancer Discov. 2020 Sep;10(9):1352-1373. doi: 10.1158/2159-8290.CD-19-1228. Epub 2020 Jun 22. Cancer Discov. 2020. PMID: 32571778 Free PMC article.
Metabolic constraints imposed by the serine and glycine-limited brain environment restrict metastatic tumor growth. How brain metastases overcome these growth-prohibitive conditions is poorly understood. ...Enhanced serine synthesis proved important for nucleotide producti …
Metabolic constraints imposed by the serine and glycine-limited brain environment restrict metastatic tumor growth. How brain metasta …
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG. Drilon A, et al. Cancer Discov. 2017 Apr;7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237. Epub 2017 Feb 9. Cancer Discov. 2017. PMID: 28183697 Free PMC article. Clinical Trial.
Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. ...Res …
Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with …
Brain metastases.
Ewend MG, Carey LA, Morris DE, Harvey RD, Hensing TA. Ewend MG, et al. Curr Treat Options Oncol. 2001 Dec;2(6):537-47. doi: 10.1007/s11864-001-0075-8. Curr Treat Options Oncol. 2001. PMID: 12057099 Review.
Metastatic tumors to the brain are an increasing cause of morbidity and mortality in patients with systemic cancers. Many new therapies used to treat systemic cancers do not penetrate the central nervous system (CNS) and do not protect patients from th …
Metastatic tumors to the brain are an increasing cause of morbidity and mortality in patients with systemic cancers. Many new therapi …
Moles and melanoma.
Chamlin SL, Williams ML. Chamlin SL, et al. Curr Opin Pediatr. 1998 Aug;10(4):398-404. doi: 10.1097/00008480-199808000-00013. Curr Opin Pediatr. 1998. PMID: 9757365 Review.
Large congenital nevi overlying the head or spine also carry risk for central nervous system involvement, which, if symptomatic, carries a grave prognosis. ...Adjuvant therapy with interferon alfa-2b holds promise for patients with metastatic melano …
Large congenital nevi overlying the head or spine also carry risk for central nervous system involvement, which, if sym …
Melanoma.
Gershenwald JE. Gershenwald JE. Oncologist. 2001;6(5):402-6. doi: 10.1634/theoncologist.6-5-402. Oncologist. 2001. PMID: 11675517 Free article.
The presentations at the American Society of Clinical Oncology 2001 meeting reported or updated the results of phase I, II, and III randomized trials and also reported important meta-analyses and retrospective studies impacting on the management of patients with …
The presentations at the American Society of Clinical Oncology 2001 meeting reported or updated the results of phase I, II, and III …
Systemic therapy for brain metastases.
Venur VA, Karivedu V, Ahluwalia MS. Venur VA, et al. Handb Clin Neurol. 2018;149:137-153. doi: 10.1016/B978-0-12-811161-1.00011-6. Handb Clin Neurol. 2018. PMID: 29307351 Review.
Central nervous system metastases cause grave morbidity in patients with advanced malignancies. ...The majority of traditional chemotherapies have shown limited activity in the central nervous system, which has been attributed to the bloo …
Central nervous system metastases cause grave morbidity in patients with advanced malignancies. ...The majority of trad …
Emerging and investigational targeted chemotherapy and immunotherapy agents for metastatic brain tumors.
McMahon JT, Faraj RR, Adamson DC. McMahon JT, et al. Expert Opin Investig Drugs. 2020 Dec;29(12):1389-1406. doi: 10.1080/13543784.2020.1836154. Epub 2020 Oct 26. Expert Opin Investig Drugs. 2020. PMID: 33040640 Review.
INTRODUCTION: Metastases to the central nervous system are the most common cause of malignant intracranial tumors in adults. ...AREAS COVERED: This study reviews novel drug regimens that are under investigation in phase 1 and 2 clinical trials. To iden …
INTRODUCTION: Metastases to the central nervous system are the most common cause of malignant intracranial tumors in ad …
Melanoma in the brain: biology and therapeutic options.
Gibney GT, Forsyth PA, Sondak VK. Gibney GT, et al. Melanoma Res. 2012 Jun;22(3):177-83. doi: 10.1097/CMR.0b013e328352dbef. Melanoma Res. 2012. PMID: 22495668 Review.
The prognosis is markedly reduced once a patient is diagnosed with central nervous system disease. Definitive therapeutic interventions with resection or stereotactic radiosurgery have improved outcomes and become standard approaches in the management of m …
The prognosis is markedly reduced once a patient is diagnosed with central nervous system disease. Definitive therapeut …
297 results